Picture of Beauty Farm Medical and Health Industry logo

2373 — Beauty Farm Medical and Health Industry News Story

0.000.00%
hk flag iconLast trade - 00:00
Consumer DefensivesSpeculativeMid CapContrarian

China's Beauty Farm H1 revenue rises on Siyanli acquisition, internal expansion

China's Beauty Farm H1 revenue rises on Siyanli acquisition, internal expansion


Overview

  • China beauty and health service provider's H1 revenue rose 29% yr/yr

  • Adjusted net profit for H1 grew nearly 40% yr/yr

  • Company attributes revenue growth to internal expansion and Siyanli acquisition


Outlook

  • BFG Group targets 20 super cities each generating more than RMB100 mln in revenue

  • Beauty Farm commits to a dividend payout ratio of at least 50% of parent net profit for the next three years

  • Naturade agrees to acquire two Hangzhou clinic and store operators for RMB10 mln, expanding its direct-store network


Result Drivers

  • SIYANLI CONSOLIDATION – Siyanli, consolidated from January, contributed RMB380 mln in H1 revenue and added growth momentum for revenue and profit

  • DIRECT-STORE VOLUME AND PRICE – Direct beauty-and-wellness revenue rose 39.8% yr/yr as visits increased 33% and average spending per visit rose 5.1%

  • PROCUREMENT AND LEASING GAINS – Gross margin widened 2.1 percentage points to 51.4%, aided by lower product procurement costs and improved property-leasing terms

  • MARKETING INVESTMENT – Selling expenses rose to RMB331 mln from RMB251 mln, primarily due to promotion and marketing spending for multi-brand upgrades


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

RMB 1.88 bln

H1 Net Income Attributable to Owners of the Company

RMB 222.20 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the personal services peer group is "buy."

  • Wall Street's median 12-month price target for Beauty Farm Medical and Health Industry Inc. is HK$38.50, about 113.2% above its August 27 closing price of HK$18.06

  • The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Aug 27 - Beauty products maker Shanghai Chicmax's H1 revenue falls on lower KANS brand sales

  • Aug 25 - China's H&H International half-year revenue rises, profit surges on margin expansion

  • Aug 26 - Nail care studio operator MiniLuxe's Q2 revenue rises, aided by expansion


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Beauty Farm Medical and Health Industry

See all news